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Background: Adult body mass index (BMI) has been associated with urinary melatonin levels in humans; however,
whether earlier-life body size is associated with melatonin, particularly among night shift workers, remains unknown.
Methods: We evaluated associations of birth weight, body shape (or somatotype) at ages 5 and 10, BMI at age 18 and
adulthood, weight change since age 18, waist circumference, waist to hip ratio, and height with creatinine-adjusted
morning urinary melatonin (6-sulfatoxymelatonin, aMT6s) levels among 1,343 healthy women (aged 32–53 at urine
collection, 1996–1999) in the Nurses’ Health Study (NHS) II cohort. Using multivariable linear regression, we computed
least-square mean aMT6s levels across categories of body size, and evaluated whether these associations were
modified by night shift work.
Results: Adult BMI was inversely associated with aMT6s levels (mean aMT6s levels = 34 vs. 50 ng/mg creatinine,
comparing adult BMI ≥30 vs. <20 kg/m2; Ptrend <0.0001); however, other measures of body size were not related
to aMT6s levels after accounting for adult BMI. Night shifts worked prior to urine collection, whether recent or
cumulatively over time, did not modify the association between adult BMI and aMT6s levels (e.g., Pinteraction = 0.72
for night shifts worked within two weeks of urine collection).
Conclusions: Our results suggest that adult BMI, but not earlier measures of body size, is associated with urinary
aMT6s levels in adulthood. These observations did not vary by night shift work status, and suggest that adult
BMI may be an important mechanism by which melatonin levels are altered and subsequently influence chronic
disease risk.
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Melatonin (5-methoxytryptamine) is a hormone with
cancer-protective properties [1], which can also enhance
endothelial function [2,3] and reduce inflammation [4].
It is secreted predominantly during darkness (i.e., at
night), with little production throughout the day [5];
however, its nocturnal production is also suppressed
within minutes if light reaches specialized retinal photo-
receptors at night (e.g., during night shift work) [6]. In* Correspondence: cor080@mail.harvard.edu
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unless otherwise stated.the general population, measurements of melatonin’s pri-
mary urinary metabolite, 6-sulfatoxymelatonin (aMT6s),
in first morning urine samples closely correlate with
plasma melatonin levels measured during the previous
night [7,8], and some epidemiologic studies have associ-
ated lower levels of aMT6s with an increased risk of
breast cancer [9-11] and several cardiovascular disease
markers[12-15]. In addition, body size throughout life (be-
ginning at birth and including adult body mass index;
BMI) has been related to breast cancer risk [16,17] and
cardiovascular disease [18,19]. Moreover, inverse associa-
tions between adult BMI and aMT6s levels have previ-
ously been observed [14,20,21]. Still, previous studies haveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tonin levels in adulthood.
Methods
The Nurses’ Health Study (NHS) II cohort was initiated in
1989, when 116,434 female registered nurses, aged 25 to
42, returned questionnaires on lifestyle, medical history,
and health status. Biennial questionnaires are used to up-
date this information, with >90% response rates for each
questionnaire cycle. First morning urine collection occurred
between 1996–1999. Collection methods and laboratory
measurement of melatonin secretion have been de-
scribed elsewhere [22-24]. Briefly, urine samples were
assayed for aMT6s concentrations as part of previous
nested case–control studies of breast cancer [9] and
hypertension [23,25], with aMT6s levels creatinine stan-
dardized (aMT6s concentrations divided by concentra-
tion of creatinine) to account for differences in urine
sample concentrations [20].
Information on body size was collected from question-
naires completed at urine collection and biennial cohort
questionnaires. A woman’s birth weight and number of
full-term pregnancies were ascertained in 1991. Women
reported height, weight at age 18, and somatotype at ages
5 and 10 in 1989. To assess somatotype, women were
asked to recall their body fatness at the specified age with
a nine-level figure diagram [26], a method which corre-
lates with weight and height measurements in childhood
(r = 0.57 at age 5, r = 0.70 at age 10) [27]. In addition,
women reported waist and hip circumference in 1993, and
current weight was ascertained at urine collection and
used to calculate adult BMI (kg/m2). Night shift work his-
tory was ascertained for the 2 weeks prior to urine collec-
tion (in number of nights worked), 2 years prior to urine
collection (in months of night shift work), and cumula-
tively throughout life (in years) up to urine collection; our
shift work assessments are detailed elsewhere [20,28].
aMT6s values that were below the limit of detection for
the assay (<0.80 ng/mL, n = 10) were set equal to this
limit. Because mean values of aMT6s concentrations
differed by cycle at which aMT6s were measured in
the breast cancer case–control study, we recalibrated
aMT6s and creatinine values using drift samples. The ori-
ginal assay results and rerun results were highly correlated
(r > 0.90) for all cycles, thus the different assays were
measuring the same analyte despite differing absolute
levels. Further details have been described elsewhere [24].
Absolute values of melatonin were similar in the breast
cancer and hypertension nested case-control studies. In
addition, we used the Generalized ESD Many-Outlier Pro-
cedure [29] to remove outliers in our aMT6s measure-
ments from the breast (n = 7) and hypertension (n = 17)
nested case-control studies. After these exclusions, there
were 1,343 controls included in these analyses.For our statistical analysis, we used the natural logarithms
of urinary aMT6s measurements to improve normality of
the outcome distribution, and estimated geometric mean
levels of melatonin across categories of each exposure using
linear regression. P-trends were calculated using continu-
ous terms for our exposures. To reduce potential mis-
classification, we also calculated somatotype averaged over
ages 5 and 10, to estimate childhood somatotype. Lastly,
we stratified our analyses of body size and melatonin
levels by median age at urine collection (<44 vs. ≥44 years)
and night shift work, and used likelihood ratio tests to
evaluate effect modification. All p-values were two-sided
and p ≤ 0.05 was considered statistically significant. We
used SAS Version 9.3 (SAS Institute, Cary, NC) for all
analyses. This study was approved by the Institutional
Review Board (IRB) of Brigham and Women’s Hospital
(Boston, Massachusetts, U.S.).
Results
There were modest differences in age and age-adjusted
baseline characteristics by quartiles of aMT6s levels
among the 1,343 women in this study (Table 1). In par-
ticular, women in the bottom quartile of aMT6s (median
aMT6s, 20.4 ng/mg creatinine; 10-90th percentile, 9.2-
27.6) were slightly older (mean age, 44.3 vs. 43.6 years),
had higher BMI (mean BMI, 26.3 vs. 23.6 kg/m2) and
greater pack-years of smoking (mean number of pack-
years, 13.6 vs. 11.9), compared to women in the top
quartile of aMT6s (median aMT6s, 84.4 ng/mg creatin-
ine; 10-90th percentile, 67.6-124.2). In addition, 89% of
all urine samples in the bottom quartile of aMT6s were
first morning spot urine sample, compared to 98% in the
top quartile.
We observed a significant inverse association between
adult BMI and aMT6s, suggesting higher levels of aMT6s
measured in adulthood in women who were leaner at
urine collection (Ptrend = <0.0001). Specifically, women
with BMI <20 kg/m2 had a mean aMT6s level of 50 ng/mg
creatinine (95% CI, 45–56), compared to women with
BMI ≥30 whose mean aMT6s level was 34 ng/mg cre-
atinine (95% CI, 30–37) (Table 2). By contrast, after ac-
counting for adult BMI, none of the other body size
measures were significantly associated with adult levels
of aMT6s (results also shown in Table 2). Further, when
we averaged childhood somatotype, we observed no as-
sociation with melatonin levels (data not shown).
Results were similar when we restricted our analyses
to non-smokers, first morning urine samples, or women
reporting no night shift work in the two weeks prior to
urine collection (data not shown). Moreover, night shift
work was not significantly associated with mean levels of
aMT6s in this sample regardless of whether we consid-
ered night shift work in two weeks, two years or cumu-
lative night shifts over a woman’s lifetime prior to urine
Table 1 Age and age-standardized characteristics at urine collection (1996–1999) of 1,343 women across quartiles of
urinary aMT6s (ng/mg creatinine) in Nurses’ Health Study IIa
Characteristics Quartiles of urinary aMT6s levels
Q1 (lowest) Q2 Q3 Q4 (highest)
N 335 336 336 336
Urinary aMT6s (ng/mg creatinine)b,c 20.4 (9.2-27.6) 37.0 (30.6-43.0) 53.0 (46.3-61.3) 84.4 (67.6-124.2)
Age (years)c 44.3 (4.5) 44.0 (4.2) 43.2 (4.4) 43.6 (4.1)
Birth weight, ≥ 7 lbs, % 64 62 59 63
Somatotype at age 5, ≥ diagram 5, % 7 7 8 5
Somatotype at age 10, ≥ diagram 5, % 11 10 10 10
Height (inches) 65.1 (2.6) 64.8 (2.5) 64.8 (2.6) 64.8 (2.4)
Body mass index at age 18 (kg/m2) 21.2 (2.9) 20.8 (2.5) 20.8 (2.9) 20.5 (2.3)
Current body mass index (kg/m2) 26.3 (6.0) 24.6 (4.7) 24.4 (4.5) 23.6 (4.0)
Weight change since age 18, ≥ 20 kg, % 26 17 17 11
Waist circumference (inches) 31.3 (5.0) 30.3 (4.2) 30.0 (4.5) 29.3 (3.6)
Waist to hip ratio 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
First morning urine sample, % 89 94 96 98
Full-term pregnancies, % 95 91 93 93
Physical activity (METs/week)d 19.6 (25.0) 20.3 (22.8) 20.5 (23.5) 20.0 (29.6)
Alcohol intake (g/day) 3.7 (6.2) 3.7 (6.7) 3.2 (5.6) 3.9 (8.2)
Pack-years of cigarette smoking 13.6 (11.8) 10.3 (8.3) 12.1 (11.1) 11.9 (10.3)
Current smoker, % 8 6 3 6
Nulliparous, % 18 18 18 20
Post-menopausal, % 11 8 6 9
Current post-menopausal hormone use, % 8 7 5 8
Ever oral contraceptive use, % 86 86 84 85
Current antidepressant use, % 10 14 14 12
Ever night shift work in 2 weeks prior to urine collection, % 9 11 7 7
Ever night shift work in 2 years prior to urine collection, % 15 14 14 10
Ever night shift work prior to urine collection, % 67 66 72 62
Values are means (SD) or percentages and are standardized to the age distribution of the study population unless otherwise noted.
aaMT6s, 6-sulfatoxymelatonin.
bValues are medians (10th-90th percentile).
cValue is not age adjusted.
dMetabolic equivalents from recreational and leisure time activities.
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Finally, associations of aMT6s levels with adult BMI
(<25, 25–29.9, ≥30 kg/m2) did not significantly differ by
shift work history (e.g., ever vs. never shift work in
2 weeks, 2 years, or cumulative night shift work prior to
urine collection; Pinteraction = 0.72, 0.07, 0.99, respectively)
or age (data not shown).
Discussion
Results from this study indicate that a higher adult
BMI may adversely affect melatonin secretion, and night
shift work did not appear to influence this observed
association. Other measures of body size were notindependently associated with aMT6s levels after ac-
counting for adult BMI. Several studies have associated
higher adult BMI with lower concentrations of aMT6s
[20,21,30,31], although results have not always been con-
sistent [32,33]. However, rodent models have provided
substantial biologic evidence on the relation between
decreased melatonin levels with obesity, weight gain
[34,35,36] and metabolic syndrome [37,38]. Thus, our
study suggests that adult BMI, not earlier-life body size,
may influence an important mediator of the circadian
system (i.e., melatonin) and later-life chronic disease
risk. However, whether earlier life BMI (e.g., at age 18)
mediates these effects cannot be ruled out completely,
Table 2 Multivariable-adjusted geometric mean concentrations of urinary aMT6s (ng/mg creatinine) at urine collection
(1996–1999) by categories of body size and night shift work among 1,343 women in Nurses’ Health Study IIa
Model 1b Model 2c





Birth weight (pounds)d <5.5 34 35 (29–43) 34 (28–42)
5.5-6.9 299 43 (40–46) 42 (39–45)
7.0-8.4 632 41 (40–44) 42 (40–44)
8.5-9.9 137 44 (40–49) 45 (40–50)
≥10 19 31 (24–41) 0.88 32 (24–42) 0.46
Somatotype at age 5 1 (leanest) 307 43 (40–46) 42 (39–45)
2 417 41 (39–44) 41 (38–43)
3 354 43 (40–46) 43 (41–46)
4 161 40 (37–44) 42 (38–46)
≥5 (heaviest) 86 41 (36–47) 0.47 44 (38–50) 0.50
Somatotype at age 10 1 (leanest) 254 41 (38–45) 40 (37–43)
2 426 43 (41–46) 42 (40–45)
3 326 42 (39–45) 42 (40–45)
4 193 41 (38–45) 42 (39–46)
≥5 (heaviest) 132 40 (36–45) 0.49 43 (39–48) 0.24
Height (inches) ≤62 236 42 (38–45) 42 (39–45)
63-64 391 43 (40–46) 43 (40–46)
65 193 43 (40–47) 43 (39–47)
66-67 316 40 (37–43) 40 (38–43)
≥68 207 41 (37–44) 0.30 41 (37–44) 0.23
Body mass index at age 18 (kg/m2) <19 306 45 (42–48) 42 (39–46)
19-19.9 260 41 (38–44) 40 (37–43)
20-22.4 516 43 (41–46) 44 (41–46)
22.5-24.9 160 35 (32–39) 38 (34–42)
25-27.4 59 36 (31–42) 41 (34–48)
≥27.5 32 39 (31–49) 0.001 45 (36–56) 0.86
Weight change since age 18 (kg) <5 452 45 (43–48) 41 (39–44)
5- < 20 633 42 (40–44) 42 (40–44)
≥20 229 36 (33–39) <0.0001 43 (38–48) 0.66
Waist circumference (inches) <26.75 163 45 (41–50) 41 (37–46)
26.75 - < 29 203 49 (45–54) 46 (42–51)
29- < 31 183 41 (37–45) 40 (36–44)
31- < 34.5 182 38 (34–41) 40 (36–44)
≥34.5 117 36 (32–40) <0.0001 43 (37–50) 0.49
Waist to hip ratio <0.72 150 46 (41–51) 44 (40–49)
0.72- < 0.75 162 44 (40–49) 42 (38–47)
0.75- < 0.79 220 42 (38–45) 41 (38–45)
0.79- < 0.82 154 38 (35–43) 40 (36–44)
≥0.82 158 40 (36–45) 0.02 43 (39–48) 0.55
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Table 2 Multivariable-adjusted geometric mean concentrations of urinary aMT6s (ng/mg creatinine) at urine collection
(1996–1999) by categories of body size and night shift work among 1,343 women in Nurses’ Health Study IIa
(Continued)
Body mass index at urine collection (kg/m2) <20 137 50 (45–56)
20-22.4 366 46 (43–49)
22.5-24.9 340 43 (40–46)
25-27.4 209 38 (35–42)
27.5-29.9 105 37 (33–41)
≥30 162 34 (30–37) <0.0001
Shift work 2 weeks prior to urine collection (nights) 0 1227 42 (41–44)
1-4 76 40 (35–46)
>4 37 38 (31–47) 0.29
Shift work 2 years prior to urine collection (months) 0 1158 42 (41–44)
1-9 78 43 (37–49)
10-19 26 38 (30–49)
≥20 73 37 (32–43) 0.08
Cumulative shift work prior to urine collection (years)e 0 447 43 (40–45)
1-9 804 41 (40–43)
≥10 85 42 (36–48) 0.37
aaMT6s, 6-sulfatoxymelatonin.
bAnalyses of body size adjusted for age at urine collection (5 year age categories), first-morning urine (yes, no), batch, number of pack-years smoked (0, <10,
10–24, ≥25 pack years), parity (nulliparous, 1–2 children, ≥3 children), physical activity in MET-hours/week (quintiles), and night shift work in 2 weeks prior to urine
collection (0, 1–4 , >4 night shifts). Multivariable analyses for shift work adjust for the same factors except they adjust for body mass index (BMI) in kg/m2 at urine
collection (<20, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30) instead of night shift work in 2 weeks prior to urine collection.
cAnalyses of body size adjust for the same factors as model 1, plus BMI in kg/m2 at urine collection (<20, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30).
dAmong women (n = 1,185) who were born full-term.
eCumulative shift work, updating baseline lifetime shift work history through urine collection.
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adult BMI.
Strengths of our study include a relatively large number
of women with aMT6s measurements and a variety of in-
formation related to body size and potential confounding
factors. Limitations include the use of a single aMT6s
measurement which is susceptible to intra-person vari-
ation; however, first morning urinary aMT6s measure-
ments remain fairly stable when measured repeatedly over
several years (ICC = 0.72, 95% CI = 0.65-0.82) [22]. In
addition, women were not asked if they worked the night
shift within the past 24-hours prior to urine collection,
which could have biased their first morning urinary aMT6s
measure, yet results remained essentially unchanged when
we excluded women with night shift work in two weeks
prior to urine collection. Lastly, we cannot rule out poten-
tial misclassification of exposure covariates. For example,
recall of self-reported somatotype at age 5 and 10 may be
susceptible to misclassification; however, we averaged
childhood somatotype to reduce potential misclassification
and results were similar. Further, self-reported childhood
somatotype recalled in later life correlates well with mea-
sured childhood body size [27], and earlier studies in ourcohort have related important health outcomes with self-
reported childhood somatotypes [39,40].Conclusion
In conclusion, our findings suggest that adult BMI is in-
versely associated with adult melatonin secretion, as
assessed by first morning urinary aMT6s concentration,
regardless of night shift work status. Additional large-
scale prospective studies with more detailed and re-
peated assessments of melatonin are needed to further
explore these associations.
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